A-POE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42

Neurology

Volumn 62, Issue 11, 2004, Pages 2116-2118

  Prince, J A ^a   Zetterberg, H ^b   Andreasen, N ^b   Marcusson, J ^c   Blennow, K ^b,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; GENE PRODUCT; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; PEPTIDE FRAGMENT;

AGED; ALLELISM; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SENILE PLAQUE; ALLELE; CEREBROSPINAL FLUID; GENETIC PREDISPOSITION; GENETICS;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; PEPTIDE FRAGMENTS;

EID: 2942557310     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000128088.08695.05     Document Type: Article

References (10)

1. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.
2. Galasko D, Clark C, Chang L, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
3. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
4. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100-105.
5. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
6. Blennow K, Ricksten A, Prince JA, et al. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm 2000;107:1065-1079.
7. Prince JA, Feuk L, Howell WM, et al. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele specific hybridization (DASH): design criteria and assay validation. Genome Res 2001; 11:152-162.
8. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-238.
9. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 2002;9:305-318.
10. Ji Y, Permanne B, Sigurdsson EM, Holtzman DM, Wisniewski T. Amyloid beta40/42 clearance across the blood-brain barrier following intraventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimer Dis 2001;3:23-30.